ST葫芦娃：中药创新药小儿胆青双解颗粒获药物临床试验批准

Core Viewpoint - ST HuLuWa (605199.SH) has received approval from the National Medical Products Administration for clinical trials of its pediatric medicine, Xiaoer Danqing Shuangjie Granules, indicating progress in the development of innovative traditional Chinese medicine for treating children's influenza [1] Company Summary - The company has announced the receipt of a clinical trial approval notice for Xiaoer Danqing Shuangjie Granules, which is classified as a Category 1.1 innovative traditional Chinese medicine [1] - The core efficacy of the drug is to clear heat and relieve toxicity, addressing both exterior and interior symptoms associated with pediatric influenza [1]